Pnp7: Compliance With Three-Times Daily Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder

Hwang, Pieway; Cosby, Arthur G.; Laberge, ME

doi:10.1016/s1098-3015(10)64035-1

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In subsequent evaluations, the United Kingdom model was refined and replicated using actual (instead of assumed) persistence data for MPH-IR and MPH-MR12 from retrospective database studies [163][164][165][166][167][168]. Again, results ranged from comparable cost effectiveness to extended dominance of MPH-MR12 versus MPH-IR [169].…”

Section: Ceas Of Long-acting Stimulantsmentioning

confidence: 99%

“…The economic argument in favor of long-acting products is grounded in their clinical efficacy [69,71,78,169,192]; the disorder-specific relevance of avoiding a midday dose in children with ADHD [183,184], supported by improved treatment persistence rates observed in retrospective database analyses [163][164][165][166][167][168]; economic modeling studies evaluating the impact of improved treatment persistence [157][158][159][160]173]; and a Canadian randomized pragmatic study broadly confirming expectations [177,191]. The economic argument in favor of long-acting products is grounded in their clinical efficacy [69,71,78,169,192]; the disorder-specific relevance of avoiding a midday dose in children with ADHD [183,184], supported by improved treatment persistence rates observed in retrospective database analyses [163][164][165][166][167][168]; economic modeling studies evaluating the impact of improved treatment persistence [157][158][159][160]173]; and a Canadian randomized pragmatic study broadly confirming expectations [177,191].…”

Section: Ceas Of Long-acting Stimulantsmentioning

confidence: 99%

See 1 more Smart Citation

The Pharmaceutical Economics of Child Psychiatric Drug Treatment

Schlander¹

2010

CPD

View full text Add to dashboard Cite

The last decade, the number of health economic evaluations has increased substantially in the field of child psychiatry. The objective of the present paper is to offer an overview of economic evaluations of child psychiatric drug treatment. Major electronic databases, as well as abstract booklets from international clinical and health economics conferences with an external peer review process, were examined to search for comparative economic evaluations of child and adolescent psychiatric drug treatment. Most studies of pharmacotreatment were cost effectiveness analyses (CEAs) concerned with attention-deficit/hyperactivity disorder (ADHD). Three evaluations were done by or on behalf of agencies as part of ADHD-related health technology assessments. A number of economic studies used patient-level data from specific randomized clinical trials, especially the NIMH-initiated MTA (in childhood ADHD) and TADS (in adolescent major depression) studies. Almost all studies relied on narrow scale symptom scales to assess effects of treatment, even when quality-adjusted life years (QALYs) were reported. In many cases, effectiveness data came from short-term studies, and extrapolation to a one-year time horizon was usually based on assumptions. Even those evaluations attempting to address longer time horizons by way of modeling did not include the impact of treatment on long-term sequelae of the conditions studied, mainly due to a paucity of robust clinical data. Nevertheless, currently available health economic evaluations broadly suggest an acceptable to attractive cost effectiveness of medication management of ADHD, whereas there is no such evidence for child psychiatric disorders other than ADHD.

show abstract

Section: Ceas Of Long-acting Stimulantsmentioning

confidence: 99%

Section: Ceas Of Long-acting Stimulantsmentioning

confidence: 99%

The Pharmaceutical Economics of Child Psychiatric Drug Treatment

Schlander¹

2010

CPD

View full text Add to dashboard Cite

show abstract

Psychotropic Medication in Children and Adolescents in Germany: Prevalence, Indications, and Psychopathological Patterns

Koelch

Prestel

Singer

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

The indication for antipsychotics was mostly behavioral symptomatology, while antidepressants were used for a wide variety of symptoms. The high proportion of children and adolescents using psychotropic medication with normal scores in the emotional and behavioral screening was remarkable. It cannot be determined whether in these cases low scores were related to improvement in symptoms or whether medication was being misused.

show abstract

Pnp7: Compliance With Three-Times Daily Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder

Cited by 2 publications

References 0 publications

The Pharmaceutical Economics of Child Psychiatric Drug Treatment

The Pharmaceutical Economics of Child Psychiatric Drug Treatment

Psychotropic Medication in Children and Adolescents in Germany: Prevalence, Indications, and Psychopathological Patterns

Contact Info

Product

Resources

About